Experienced in Congenital Mesoblastic Nephroma

Dr. Katie S. Murray

Urology
New York University
560 1st Ave, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
17 Years of Experience
Experienced in Congenital Mesoblastic Nephroma
New York University
560 1st Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Katie Murray is an Urologist in New York, New York. Dr. Murray has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Congenital Mesoblastic Nephroma. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), Nephrectomy, and Ureteroscopy.

Her clinical research consists of co-authoring 91 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Urology
Licenses
Urology in MO
Hospital Affiliations
Bellevue Hospital Center
Nyu Langone Hospitals
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

NEW YORK UNIVERSITY
560 1st Ave, New York, NY 10016
Other Locations
NEW YORK UNIVERSITY
111 Broadway, New York, NY 10006

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Procedure, Drug, Other, Radiation
Study Drugs: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin acetate, Histrelin acetate, Leuprolide acetate, Nilutamide, Prednisone, Triptorelin
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Gemcitabine Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Other, Drug
Study Drug: Oxybutynin Chloride
Study Phase: Phase 2
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Drug
Study Drug: UGN-102
Study Phase: Phase 3
Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Ureteral Stent Symptoms After Ureteroscopy: a Randomized Controlled Trial
Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Ureteral Stent Symptoms After Ureteroscopy: a Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: October 24, 2024
Intervention Type: Drug
Study Drug: Pregabalin
Study Phase: Phase 2/Phase 3
A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partial Nephrectomy
A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partial Nephrectomy
Enrollment Status: Terminated
Publish Date: October 25, 2023
Intervention Type: Drug
Study Drug: Lidocaine
Study Phase: Phase 4
Phase 2 Trial of NanoPac Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy
Phase 2 Trial of NanoPac Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy
Enrollment Status: Terminated
Publish Date: March 29, 2022
Intervention Type: Drug
Study Drug: NanoPac
Study Phase: Phase 2
Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot
Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot
Enrollment Status: Completed
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 10 Less Clinical Trials

91 Total Publications

Erratum: TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
Erratum: TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 09, 2025
Similar Doctors
Distinguished in Congenital Mesoblastic Nephroma
Dr. Mark A. Perlmutter
Urology
Distinguished in Congenital Mesoblastic Nephroma
Dr. Mark A. Perlmutter
Urology

Advanced Urology Associates Enterprises

2401 Hwy 35, 
Manasquan, NJ 
 (43.2 miles away)
732-800-3013
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Perlmutter is an Urologist in Manasquan, New Jersey. Dr. Perlmutter is rated as a Distinguished provider by MediFind in the treatment of Congenital Mesoblastic Nephroma. His top areas of expertise are Congenital Mesoblastic Nephroma, Enlarged Prostate (BPH), Boils, Ureteroscopy, and Bladder Reconstruction. Dr. Perlmutter is currently accepting new patients.

Distinguished in Congenital Mesoblastic Nephroma
Dr. Alexander Kirshenbaum
Urology
Distinguished in Congenital Mesoblastic Nephroma
Dr. Alexander Kirshenbaum
Urology

Summit Medical Group PA

1 Diamond Hill Rd, 
Berkeley Heights, NJ 
 (23.3 miles away)
908-273-4300
Languages Spoken:
English, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexander Kirshenbaum is an Urologist in Berkeley Heights, New Jersey. Dr. Kirshenbaum is rated as a Distinguished provider by MediFind in the treatment of Congenital Mesoblastic Nephroma. His top areas of expertise are Enlarged Prostate (BPH), Hydronephrosis, Bilateral Hydronephrosis, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Kirshenbaum is currently accepting new patients.

Distinguished in Congenital Mesoblastic Nephroma
Dr. Gregg E. Zimmerman
Urology
Distinguished in Congenital Mesoblastic Nephroma
Dr. Gregg E. Zimmerman
Urology

Titan Health Partners LLC

J2 Brier Hill Ct, 
East Brunswick, NJ 
 (32.9 miles away)
732-390-7750
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregg Zimmerman is an Urologist in East Brunswick, New Jersey. Dr. Zimmerman is rated as a Distinguished provider by MediFind in the treatment of Congenital Mesoblastic Nephroma. His top areas of expertise are Congenital Mesoblastic Nephroma, Enlarged Prostate (BPH), Perirenal Abscess, Vasectomy, and Reconstructive Urology Surgery. Dr. Zimmerman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Murray's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile